Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AYTU NASDAQ:CLSD NYSE:NNVC NASDAQ:PALI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYTUAytu BioPharma$1.74-6.5%$2.35$0.95▼$2.82$17.24M0.22551,369 shs612,281 shsCLSDClearside Biomedical$4.04+8.3%$5.65$3.32▼$24.75$21.17M2.11116,993 shs99,105 shsNNVCNanoViricides$1.42+1.4%$1.51$0.94▼$1.92$22.82M1.15226,690 shs42,341 shsPALIPalisade Bio$0.90+16.2%$0.78$0.53▼$4.32$8.19M1.41.12 million shs1.22 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYTUAytu BioPharma-9.71%-21.52%-18.42%-11.43%-23.46%CLSDClearside Biomedical-6.75%-4.11%-37.09%-67.71%-77.80%NNVCNanoViricides-1.41%-1.41%-2.10%0.00%+3.70%PALIPalisade Bio+12.95%+29.26%+13.93%+10.43%-75.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYTUAytu BioPharma$1.74-6.5%$2.35$0.95▼$2.82$17.24M0.22551,369 shs612,281 shsCLSDClearside Biomedical$4.04+8.3%$5.65$3.32▼$24.75$21.17M2.11116,993 shs99,105 shsNNVCNanoViricides$1.42+1.4%$1.51$0.94▼$1.92$22.82M1.15226,690 shs42,341 shsPALIPalisade Bio$0.90+16.2%$0.78$0.53▼$4.32$8.19M1.41.12 million shs1.22 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYTUAytu BioPharma-9.71%-21.52%-18.42%-11.43%-23.46%CLSDClearside Biomedical-6.75%-4.11%-37.09%-67.71%-77.80%NNVCNanoViricides-1.41%-1.41%-2.10%0.00%+3.70%PALIPalisade Bio+12.95%+29.26%+13.93%+10.43%-75.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYTUAytu BioPharma 3.00Buy$9.17419.36% UpsideCLSDClearside Biomedical 2.17Hold$63.001,476.97% UpsideNNVCNanoViricides 0.00N/AN/AN/APALIPalisade Bio 3.00Buy$12.001,276.15% UpsideCurrent Analyst Ratings BreakdownLatest PALI, CLSD, NNVC, and AYTU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/25/2025AYTUAytu BioPharmaMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $7.009/25/2025AYTUAytu BioPharmaAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $12.507/18/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$75.007/18/2025CLSDClearside BiomedicalChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral7/18/2025CLSDClearside BiomedicalStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$30.007/17/2025CLSDClearside BiomedicalJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/17/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeModerate Buy ➝ Hold$45.007/1/2025AYTUAytu BioPharmaLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.006/30/2025AYTUAytu BioPharmaAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 9/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYTUAytu BioPharma$66.38M0.26$0.32 per share5.49$4.64 per share0.38CLSDClearside Biomedical$1.66M12.61N/AN/A($7.68) per share-0.52NNVCNanoViricidesN/AN/AN/AN/A$0.66 per shareN/APALIPalisade Bio$250K31.81N/AN/A$2.71 per share0.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYTUAytu BioPharma-$15.84M-$2.82N/A∞N/A-20.43%13.77%3.28%11/12/2025 (Estimated)CLSDClearside Biomedical-$34.35M-$5.55N/AN/AN/A-665.19%N/A-124.15%11/11/2025 (Estimated)NNVCNanoViricides-$8.29M-$0.70N/A∞N/AN/A-87.90%-78.69%N/APALIPalisade Bio-$14.44M-$4.06N/AN/AN/AN/A-214.94%-135.09%11/11/2025 (Estimated)Latest PALI, CLSD, NNVC, and AYTU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/23/2025Q4 2025AYTUAytu BioPharma-$0.02-$0.26-$0.24-$2.92$18.06 million$15.14 million8/11/2025Q2 2025PALIPalisade Bio-$0.48-$0.58-$0.10-$0.58N/AN/A8/8/2025Q2 2025CLSDClearside Biomedical-$1.80-$0.90+$0.90-$0.06$0.50 million$0.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYTUAytu BioPharmaN/AN/AN/AN/AN/ACLSDClearside BiomedicalN/AN/AN/AN/AN/ANNVCNanoViricidesN/AN/AN/AN/AN/APALIPalisade BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYTUAytu BioPharma0.571.260.87CLSDClearside BiomedicalN/A3.873.87NNVCNanoViricidesN/A3.442.47PALIPalisade BioN/A1.621.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYTUAytu BioPharma33.49%CLSDClearside Biomedical18.75%NNVCNanoViricides10.30%PALIPalisade Bio11.79%Insider OwnershipCompanyInsider OwnershipAYTUAytu BioPharma3.60%CLSDClearside Biomedical6.70%NNVCNanoViricides4.60%PALIPalisade Bio0.73%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAYTUAytu BioPharma1609.91 million8.65 millionNot OptionableCLSDClearside Biomedical305.24 million4.89 millionOptionableNNVCNanoViricides2016.07 million14.92 millionOptionablePALIPalisade Bio109.12 million9.05 millionNot OptionablePALI, CLSD, NNVC, and AYTU HeadlinesRecent News About These CompaniesPalisade Bio Adjourns Stockholder Meeting Due to Quorum1 hour ago | tipranks.comPalisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum3 hours ago | globenewswire.comPalisade Bio, Inc. (NASDAQ:PALI) Short Interest UpdateSeptember 20, 2025 | americanbankingnews.comPalisade Bio (NASDAQ:PALI) Stock Rating Upgraded by Wall Street ZenSeptember 20, 2025 | americanbankingnews.comPalisade Bio Reschedules Stockholder Meeting Due to Quorum IssueSeptember 18, 2025 | tipranks.comPalisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of QuorumSeptember 18, 2025 | globenewswire.comPalisade Bio reports results from PALI-2108 Phase 1b dataSeptember 17, 2025 | msn.comPalisade Bio Reports Positive PALI-2108 Phase 1b Clinical DataSeptember 17, 2025 | globenewswire.comHealth Canada clears Palisade Bio’s trial of Crohn’s disease treatmentSeptember 8, 2025 | finance.yahoo.comPalisade Bio receives Health Canada clearance for Phase 1b PALI-2108 trialSeptember 6, 2025 | msn.comPalisade Bio receives Health Canada clearance for Phase 1b PALI-2108 trialSeptember 6, 2025 | msn.comPalisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD)September 6, 2025 | markets.businessinsider.comPalisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD)September 6, 2025 | markets.businessinsider.comPalisade Bio Advances PALI-2108 as First Dual-Acting Therapy for Fibrostenotic Crohn's Disease, Dosing to Begin H2 2025September 5, 2025 | quiverquant.comQPalisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)September 5, 2025 | globenewswire.comPalisade Bio releases virtual KOL Connect segment on PALI-2108August 25, 2025 | msn.comPalisade Bio Features Dr. Brian Feagan in Discussion on Fibrostenotic Crohn's Disease and Innovations in IBD Treatment with PALI-2108August 25, 2025 | quiverquant.comQPalisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108August 25, 2025 | globenewswire.comPalisade Bio files to sell 8.9M shares of common stock for holdersAugust 16, 2025 | msn.comPalisade reports outcomes from Phase Ib ulcerative colitis studyAugust 11, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePALI, CLSD, NNVC, and AYTU Company DescriptionsAytu BioPharma NASDAQ:AYTU$1.74 -0.12 (-6.45%) Closing price 04:00 PM EasternExtended Trading$1.74 0.00 (-0.29%) As of 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.Clearside Biomedical NASDAQ:CLSD$4.04 +0.31 (+8.31%) Closing price 04:00 PM EasternExtended Trading$4.09 +0.05 (+1.21%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.NanoViricides NYSE:NNVC$1.42 +0.02 (+1.43%) Closing price 04:00 PM EasternExtended Trading$1.40 -0.01 (-1.06%) As of 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.Palisade Bio NASDAQ:PALI$0.90 +0.13 (+16.20%) Closing price 04:00 PM EasternExtended Trading$0.87 -0.03 (-2.81%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Institutional Buying Sets a High Floor for Microsoft Stock High-Momentum ETFs to Mine for Gold, Silver, and Bitcoin It's a Good Time to Build a Position in KB Home Alphabet: Time to Take Profits, Buy, or Wait for a Pullback? NuScale, Rocket Lab Face Heavy Insider Selling After Surges Why Wall Street Is Betting Billions on Oklo's Nuclear Vision CrowdStrike’s Investor Day Sparks Bullish Momentum Cintas Stock Sends a Clear Buy Signal as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
